UBS AM’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

UBS AM’s Portfolio CNST Stock Details CNST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-37,958	Closed	-$1.28M	–	2799
2021 Q2	$1.28M	Buy	37,958 +6,589	+21%	+$168K	﹤0.01%	2072
2021 Q1	$734K	Buy	31,369 +5,300	+20%	+$161K	﹤0.01%	2223
2020 Q4	$751K	Sell	26,069 -3,900	-13%	-$98.2K	﹤0.01%	2124
2020 Q3	$607K	Buy	29,969 +9,117	+44%	+$223K	﹤0.01%	2047
2020 Q2	$627K	Buy	+20,852	New	+$751K	﹤0.01%	2021

UBS AM's CNST Position: Q3 2021 in Review

UBS AM sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q3 2021, closing a stake of 37,958 shares — an estimated $1.28M sold.

UBS AM first reported a position in CNST in Q2 2020 and held it in 5 quarters. The position peaked at $1.28M in Q2 2021. 0 funds tracked by Wall St. Rank hold CNST as of Q3 2021.

UBS AM reported no remaining Constellation Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
UBS AM sold 37,958 Constellation Pharmaceuticals, Inc. shares in Q3 2021, an estimated $1.28M.
UBS AM first reported a position in Constellation Pharmaceuticals, Inc. in Q2 2020 and held it in 5 quarters.
UBS AM's Constellation Pharmaceuticals, Inc. position peaked at $1.28M in Q2 2021.
0 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q3 2021.

Based on UBS AM's 13F filing for Q3 2021, filed 15 Nov 2021.